Similarly, in the adjuvant setting, a 2020 phase III trial in resected stage IB–IIIA EGFR-mutant NSCLC reported DFS improvement with osimertinib in the overall population and in both smoking subgroups [122,123]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.